Jointown Pharmaceutical Group Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Jointown Pharmaceutical Group wird ein jährliches Gewinn- und Umsatzwachstum von 17.1% bzw. 8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 15% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.4% betragen.

Wichtige Informationen

17.1%

Wachstumsrate der Gewinne

15.0%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	23.0%
Wachstumsrate der Einnahmen	8.0%
Zukünftige Eigenkapitalrendite	10.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss

Aug 29

Recent updates

We Think Jointown Pharmaceutical Group (SHSE:600998) Can Stay On Top Of Its Debt

Nov 17

Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss

Aug 29

Earnings Working Against Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Share Price

Aug 26

These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well

Aug 01

Jointown Pharmaceutical Group (SHSE:600998) Has More To Do To Multiply In Value Going Forward

Jun 07

Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Earnings Are Not Doing Enough For Some Investors

May 21

Calculating The Intrinsic Value Of Jointown Pharmaceutical Group Co., Ltd (SHSE:600998)

Apr 05

Gewinn- und Umsatzwachstumsprognosen

SHSE:600998 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	179,870	3,082	N/A	4,296	4
12/31/2025	167,170	2,721	N/A	2,254	5
12/31/2024	156,373	2,353	N/A	4,515	4
9/30/2024	149,205	2,047	317	1,291	N/A
6/30/2024	147,953	2,039	82	1,029	N/A
3/31/2024	148,519	2,151	3,155	4,116	N/A
12/31/2023	150,140	2,174	3,699	4,748	N/A
9/30/2023	151,842	2,170	5,217	6,257	N/A
6/30/2023	151,797	2,159	5,409	6,559	N/A
3/31/2023	147,366	2,194	2,395	3,611	N/A
12/31/2022	140,424	2,085	2,743	3,986	N/A
9/30/2022	133,260	1,782	3,638	4,886	N/A
6/30/2022	128,411	1,545	1,345	2,656	N/A
3/31/2022	124,929	2,141	1,862	3,234	N/A
12/31/2021	122,407	2,448	2,073	3,459	N/A
9/30/2021	122,634	3,339	282	1,907	N/A
6/30/2021	121,491	3,988	3,113	4,802	N/A
3/31/2021	116,315	3,258	2,009	3,574	N/A
12/31/2020	110,860	3,075	1,987	3,444	N/A
9/30/2020	106,438	2,849	2,930	4,117	N/A
6/30/2020	102,417	2,242	2,025	3,152	N/A
3/31/2020	102,007	1,976	2,349	3,480	N/A
12/31/2019	99,497	1,727	1,576	2,768	N/A
9/30/2019	96,769	1,588	1,479	2,737	N/A
6/30/2019	93,116	1,547	1,882	3,123	N/A
3/31/2019	89,589	1,446	583	1,833	N/A
12/31/2018	87,136	1,341	-593	1,222	N/A
9/30/2018	83,230	1,262	-1,949	-231	N/A
6/30/2018	80,163	1,189	N/A	-2,213	N/A
3/31/2018	77,339	1,481	N/A	-2,221	N/A
12/31/2017	73,943	1,446	N/A	-1,012	N/A
9/30/2017	70,783	1,374	N/A	-2,586	N/A
6/30/2017	67,999	1,360	N/A	-198	N/A
3/31/2017	64,925	921	N/A	1,382	N/A
12/31/2016	61,557	877	N/A	431	N/A
9/30/2016	58,367	777	N/A	1,748	N/A
6/30/2016	55,482	754	N/A	193	N/A
3/31/2016	53,091	718	N/A	-783	N/A
12/31/2015	49,589	695	N/A	436	N/A
9/30/2015	46,895	640	N/A	-1,088	N/A
6/30/2015	45,049	602	N/A	-1,287	N/A
3/31/2015	43,171	566	N/A	-312	N/A
12/31/2014	41,068	561	N/A	-172	N/A
9/30/2014	39,273	533	N/A	-450	N/A
6/30/2014	37,189	509	N/A	-702	N/A
3/31/2014	35,150	493	N/A	-1,230	N/A
12/31/2013	33,438	478	N/A	138	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600998Das prognostizierte Gewinnwachstum (17.1% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 600998Die Erträge des Unternehmens (17.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (26.2% pro Jahr).

Hohe Wachstumserträge: 600998Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 600998Die Einnahmen des Unternehmens (8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 600998Die Einnahmen des Unternehmens (8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600998Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.4%).

Jointown Pharmaceutical Group Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 14% to CN¥6.41

Consensus EPS estimates fall by 13%

Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss

Consensus EPS estimates fall by 11%

Price target increased by 23% to CN¥9.48

Price target decreased by 10% to CN¥7.70

Recent updates

We Think Jointown Pharmaceutical Group (SHSE:600998) Can Stay On Top Of Its Debt

Price target decreased by 14% to CN¥6.41

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Jointown Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 17%

Consensus EPS estimates fall by 13%

Here's What Analysts Are Forecasting For Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) Following Its Earnings Miss

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Earnings Working Against Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Share Price

These 4 Measures Indicate That Jointown Pharmaceutical Group (SHSE:600998) Is Using Debt Reasonably Well

Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 27, 2024

Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces an Equity Buyback for CNY 300 million worth of its shares.

Jointown Pharmaceutical Group (SHSE:600998) Has More To Do To Multiply In Value Going Forward

Investor sentiment deteriorates as stock falls 23%

Jointown Pharmaceutical Group Co., Ltd's (SHSE:600998) Earnings Are Not Doing Enough For Some Investors

Consensus EPS estimates fall by 11%

Jointown Pharmaceutical Group Co., Ltd, Annual General Meeting, May 24, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 23% to CN¥9.48

Calculating The Intrinsic Value Of Jointown Pharmaceutical Group Co., Ltd (SHSE:600998)

Jointown Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment improves as stock rises 18%

Jointown Pharmaceutical Group Co., Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024

Price target decreased by 10% to CN¥7.70

Third quarter 2023 earnings released: EPS: CN¥1.16 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 30%

Price target increased by 15% to CN¥12.04

Second quarter 2023 earnings released: EPS: CN¥0.28 (vs CN¥0.29 in 2Q 2022)

Jointown Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 29, 2023

Price target increased by 7.4% to CN¥15.62

First quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.23 in 1Q 2022)

Price target increased by 8.5% to CN¥14.54

Less than half of directors are independent

Consensus forecasts updated

Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.12 in 3Q 2021)

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.77 in 2Q 2021)

Consensus EPS estimates fall by 48%

Price target decreased to CN¥13.40

Jointown Pharmaceutical Group Co., Ltd (SHSE:600998) announces an Equity Buyback for CNY 600 million worth of its shares.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.48 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.77 (vs CN¥0.37 in 2Q 2020)

Price target decreased to CN¥19.00

First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.32 in 1Q 2020)

New 90-day low: CN¥17.10

Price target raised to CN¥20.35

New 90-day high: CN¥18.60

Analysts update estimates

Third quarter earnings released

Annual earnings released: Earnings beat expectations

Jointown Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998) intends to acquire remaining 51% stake in Hubei Buchang Jiuzhoutong Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 21.8 million.

New 90-day low - CN¥17.39

Earnings released

New 90-day high - CN¥20.19

Jointown Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken